American Association for Cancer Research
Browse

Supplementary Figure S2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Download (5.65 MB)
figure
posted on 2023-05-22, 14:20 authored by Ritu Chaudhary, Robbert J.C. Slebos, Leenil C. Noel, Feifei Song, Maria I. Poole, Dirk S. Hoening, Juan C. Hernandez-Prera, Jose R. Conejo-Garcia, Jose A. Guevara-Patino, Xuefeng Wang, Mengyu Xie, Aik Choon Tan, Christine H. Chung

(A, B) Representative mIHC images showing staining of nuclei (blue), tumor cell (orange - PCK) and selected immune checkpoint markers in each molecular subgroup. (A) Images show four lymphoid markers - CD3+ T-cells (Green), CD8+ cytotoxic T-cells (Yellow), CD69+ activated T-cells (Red) and CD103+ resident memory T-cells (Cyan). (B) Images show three myeloid markers – HLA-DR+ APCs (Green), MHCII+ APCs (Cyan) and CD163+ M2 macrophages (Yellow). (C) Linear model showing correlation between PD-L1 CPS and Immune, Mixture and Hypoxia subgroups. (D-E) Boxplots showing cell counts distribution of different immune markers among the primary (n = 63) and recurrent (n = 20) tumors in TMA mIHC cohort. Students t-tests were used to test for significant differences between the groups.

Funding

HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)

HHS | NIH | National Cancer Institute (NCI)

James and Esther King Biomedical Research Grant

History

ARTICLE ABSTRACT

While the hypoxic and immunosuppressive TME of HNSCC has been well described, comprehensive evaluation of the immune cell components and signaling pathways contributing to immunotherapy resistance has been poorly characterized. We further identified additional molecular determinants and potential therapeutic targets of the hypoxic TME to fully leverage currently available targeted therapies that can be administered with immunotherapy.